Skip to main content
. Author manuscript; available in PMC: 2014 Sep 9.
Published in final edited form as: Science. 2014 Jan 17;343(6168):309–313. doi: 10.1126/science.1248627

Fig. 4. MYH9 is a bona fide tumor suppressor in human HNSCC.

Fig. 4

(A) p53 induction in primary human keratinocytes treated with the myosin ATPase inhibitor blebbistatin and with the DDR inducer doxorubicin. GAPDH levels are shown as loading control. (B) Myosin IIa quantifications on 362 samples of human healthy skin, skin SCCs, and HNSCCs. A substantial fraction of cases show absent or reduced myosin IIa expression. (C) Decreased MYH9 mRNA expression correlates with shortened survival. Kaplan-Meier analysis compares overall survival of TCGA HNSCC patients stratified according to the lowest (≤5th percentile) MYH9 expression versus the rest (>5th percentile) (n = 166, P = 0.0044, log-rank test).